Positive Topline Results from Interim Analysis of Ph 3 ACTION-1 for RYZ101 Announced in Patients with GEP-NETs October 14, 2026
Opamtistomig Granted FDA Fast Track Designation for 1L Advanced or Metastatic Biliary Tract Cancer October 14, 2026
First Patient dosed in Ph 3 RASolute 309 Trial of RASONQUE™ (daraxonrasib) + Zoldonrasib in 1L Metastatic RAS G12D Pancreatic Cancer October 14, 2026
Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations From the US FDA for CRC and NSCLC October 14, 2026
FDA approved adjuvant Tecentriq and Tecentriq Hybreza in combination with a fluoropyrimidine and oxaliplatin for the treatment of stage III dMMR colon cancer October 14, 2026
First Patient Enrolled in Global Ph 3 Trial of Cadonilimab vs Nivolumab in 1L Gastric Cancer October 6, 2026
Results from VIRAGE Ph 2b Trial of VCN-01 in Metastatic Pancreatic Cancer Published in Nature Medicine October 6, 2026
FDA Approves Lyrfigtu (Lirafugratinib) for 2L Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement Treatment Option October 1, 2026
Nature Medicine Publication of ASPEN-06 Ph 2 Data Demonstrates Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric Cancer October 1, 2026
MAA submitted to EMA for Lirafugratinib for Advanced/Metastatic Cholangiocarcinoma (CCA) Harboring FGFR2 Fusions or Rearrangements September 22, 2026
US FDA Breakthrough Therapy Designation for RASONQUE™ (daraxonrasib) + Chemo for 1L Metastatic Pancreatic Cancer September 22, 2026
FDA approves BEXLUTRY lutetium Lu 177 dotatate injection for adults with SSTR-positive GEP-NETs September 22, 2026
HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy September 9, 2026
AIM ImmunoTech Secures Broad US Patent for Rintatolimod (Ampligen®) Used in Combination with Keytruda, Expanding Oncology IP Protection for Ampligen Through 2039 September 9, 2026